CanaryBio Surpasses 400 Patients Recruited for Global Phase 3 Clinical Trial

[Asia Economy Reporter Jang Hyowon] Canaria Bio announced on the 11th that it has reached 401 patients in the global Phase 3 clinical trial recruitment of Oreogobomab for ovarian cancer patients, surpassing two-thirds of the total recruitment target of 602 patients.

Oreogobomab is a new drug that showed an encouraging result of progression-free survival (PFS) extended by 30 months to 42 months compared to the existing standard treatment in the global Phase 2 clinical trial. The global Phase 3 clinical trial of Oreogobomab is being conducted with Dr. Angeles Secord of the Duke University Cancer Institute in the United States as the clinical lead, targeting newly diagnosed ovarian cancer patients at 152 sites across 16 countries.

This global Phase 3 clinical trial is divided into two cohorts: adjuvant chemotherapy and neoadjuvant chemotherapy. The U.S. FDA has indicated that approval of the new drug is possible if either one of the cohorts is successful.

With patient recruitment reaching two-thirds of the target, the interim results are expected to be announced in the third quarter of next year as originally planned. Additionally, in the adjuvant chemotherapy cohort, 73% of patients will have their final results announced once the progression-free survival (PFS) period ends.

CEO Nahanik emphasized, “It is difficult to achieve a progression-free survival (PFS) of more than 12 months with only the current standard treatments, Paclitaxel and Carboplatin. After the interim results announcement in the third quarter of next year, the probability of success can be seen to increase meaningfully each month as time passes,” adding, “The countdown has now begun.”

This content was produced with the assistance of AI translation services.